Connection
David Camidge to Exanthema
This is a "connection" page, showing publications David Camidge has written about Exanthema.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.036 |
|
|
|
-
Horn L, Gettinger S, Camidge DR, Smit EF, Janjigian YY, Miller VA, Pao W, Freiwald M, Fan J, Wang B, Chand VK, Groen HJM. Continued use of afatinib with the addition of cetuximab after progression on afatinib in patients with EGFR mutation-positive non-small-cell lung cancer and acquired resistance to gefitinib or erlotinib. Lung Cancer. 2017 11; 113:51-58.
Score: 0.036